Regulatory updates, compliance insights, and industry analysis from the ACPL team.
India's PWM Amendment Rules 2026 (G.S.R. 237(E)) impose binding recycled content targets, new importer obligations, and ₹1 crore penalties. Act…
Read More
he Central Drugs Standard Control Organization (CDSCO) has issued a new public notice dated 4 May 2026 regarding the disposal…
Read MoreThe March 2026 FSSAI licensing overhaul changes the rules for nutraceutical FBOs — from perpetual validity to new thresholds. Here's…
Read MoreIndia's NDPS regulatory landscape shifted significantly in late 2025 and early 2026. Here's what pharmaceutical companies must act on now.
Read MoreCDSCO's unified digital ecosystem launches with May 13 deadline. New AI tools for faster approvals and pending application cleanup underway.
Read MoreCDSCO's March 2026 reforms introduce prior intimation for BA/BE studies, reducing approval times from 90 to 45 days for faster…
Read MoreNew rules effective March 7, 2026 cut approval timelines from 90 to 45 days. Prior intimation replaces licenses for low-risk…
Read MoreRecent searches reveal minimal NDPS notifications in Q1 2026, while related pharmaceutical regulations show active enforcement. Key compliance insights.
Read MoreCDSCO threatens rejection of 2+ year pending applications by Feb 14, 2026. New IVD import guidance and cosmetic enforcement actions…
Read More
Key highlights from the CDSCO circular on “Testing of drugs for grant of permissions for import/manufacture of New Drug for…
Read More